HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses

Cristina Scielzo, Paolo Ghia, Antonio Conti, Angela Bachi, Giuseppe Guida, Massimo Geuna, Massimo Alessio, Federico Caligaris-Cappio

Research output: Contribution to journalArticlepeer-review

Abstract

We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgVH mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HSl). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.

Original languageEnglish
Pages (from-to)1644-1650
Number of pages7
JournalJournal of Clinical Investigation
Volume115
Issue number6
DOIs
Publication statusPublished - Jun 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses'. Together they form a unique fingerprint.

Cite this